Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

The Multi-CDK Inhibitor Dinaciclib Shows Synergistic Activity with the BET Inhibitor PLX51107 and Reverses BET Resistance through Inhibition of Canonical Wnt Signaling in Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 3075–3076.

https://doi.org/10.1182/blood-2022-160277

Published: 2022

Journal Articles

Elucidating the Mechanism of Action (MOA) of Navtemadlin, an MDM2 Inhibitor, and Its Synergy with Gilteritinib in Myeloid Malignancies

Sara Elgamal, Tracy Clevenger, Michael Gulrajani, Jean Cheung, Erin G. Jeremy, Sydney Fobare, Shelley Orwick, Ellen J. Sass, Erin Hertlein, Karilyn T. Larkin, Todd Covey, Wayne P. Rothbaum, John C. Byrd

Blood (2022) 140 (Supplement 1): 5936–5938.

https://doi.org/10.1182/blood-2022-159568

Published: 2022

Journal Articles

Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])

Blood (2022) 140 (Supplement 1): 936–939.

https://doi.org/10.1182/blood-2022-165395

Published: 2022

Journal Articles

Molecular and Clinical Features of FLT3 Juxtamembrane Domain Point Mutations (muts) in Acute Myeloid Leukemia (AML)

Nadeen Anabtawi, Jessica Kohlschmidt, Daelynn Buelow, Shelley Orwick, Kennedy Coleman, Krzysztof Mrózek, Jonathan E. Kolitz, Bayard L. Powell, William G. Blum, Maria R. Baer, John C. Byrd, Wendy Stock, Geoffrey L. Uy, Ann-Kathrin Eisfeld, Sharyn Baker, James S. Blachly

Blood (2022) 140 (Supplement 1): 6244–6246.

https://doi.org/10.1182/blood-2022-171222

Published: 2022

Journal Articles

Identification of PTPN11 mutations As Early Events in the Development of Acute Myeloid Leukemia

Sydney Fobare, Shelley Orwick, Jessica Kohlschmidt, Tom Sesterhenn, Krzysztof Mrózek, Ben Wronowski, Megan Johnstone, Andrew J. Carroll, Richard M. Stone, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, John P Perentesis, Ann-Kathrin Eisfeld, Erin Hertlein, John C. Byrd

Blood (2022) 140 (Supplement 1): 743–744.

https://doi.org/10.1182/blood-2022-160323

Published: 2022

Journal Articles

Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study

Krzysztof Mrózek, Jessica Kohlschmidt, James S. Blachly, Deedra Nicolet, Andrew J. Carroll, Kellie J. Archer, Alice S. Mims, Karilyn T. Larkin, Shelley Orwick, Christopher C. Oakes, Jonathan E. Kolitz, Bayard L. Powell, William G. Blum, Guido Marcucci, Maria R. Baer, Geoffrey L. Uy, Wendy Stock, John C. Byrd, Ann-Kathrin Eisfeld

Blood (2022) 140 (Supplement 1): 6318–6320.

https://doi.org/10.1182/blood-2022-167352

Published: 2022

Journal Articles

High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance)

Blood (2021) 138 (Supplement 1): 221.

https://doi.org/10.1182/blood-2021-151072

Published: 2021

Journal Articles

Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes

Blood (2021) 138 (Supplement 1): 685.

https://doi.org/10.1182/blood-2021-153015

Published: 2021

Journal Articles

VIP152 Is a Novel CDK9 Inhibitor with Efficacy in Chronic Lymphocytic Leukemia

Steven Sher, Larry Beaver, Katie Williams, Shelley Orwick, Brandi R. Walker, Charles Thomas Gregory, Matthew Purcell, Alexander Pan, Pearlly S. Yan, Amy J. Johnson, Melanie M. Frigault, Joy M. Greer, Ahmed Hamdy, Raquel Izumi, Stuart Hwang, James S. Blachly, John C. Byrd, Rosa Lapalombella

Blood (2021) 138 (Supplement 1): 270.

https://doi.org/10.1182/blood-2021-153812

Published: 2021

Journal Articles

High-Dimensional Analysis Identifies Mechanisms of Gilteritinib Resistance in FLT3 -Mutated AML

Daelynn R Buelow, Bhavana Bhatnagar, Jae Yoon Jeon, Megan Zavorka Thomas, Eric Eisenmann, Jack Stromatt, Shelley Orwick, Navjot Pabla, James S. Blachly, Sharyn Baker, Bradley W Blaser

Blood (2021) 138 (Supplement 1): 207.

https://doi.org/10.1182/blood-2021-148569

Published: 2021

Journal Articles

Social Deprivation Independently Predicts Survival in Younger Patients with Acute Myeloid Leukemia (Alliance)

Melanie T Rebechi, Jessica Kohlschmidt, Krzysztof Mrózek, Deedra Nicolet, Alice S. Mims, James S. Blachly, Shelley Orwick, William Blum, Bayard L. Powell, Geoffrey L. Uy, Richard M. Stone, John C. Byrd, Electra D. Paskett, Jesse Plascak, Ann-Kathrin Eisfeld

Blood (2021) 138 (Supplement 1): 1983.

https://doi.org/10.1182/blood-2021-149647

Published: 2021

Journal Articles

White Blood Cell Count (WBC) Levels Are Associated with Molecular Profiles and Are Independent Outcome Predictors in Acute Myeloid Leukemia (AML) Patients (Pts) (Alliance)

Michael P. Ozga, Deedra Nicolet, Krzysztof Mrózek, Christopher J. Walker, James S. Blachly, Jessica Kohlschmidt, Shelley Orwick, Andrew J Carroll, Richard A. Larson, Jonathan E Kolitz, Bayard L. Powell, Richard M. Stone, John C. Byrd, Ann-Kathrin Eisfeld, Alice S. Mims

Blood (2021) 138 (Supplement 1): 3369.

https://doi.org/10.1182/blood-2021-151610

Published: 2021

Journal Articles

Epigenetic Phenocopying Expands Molecular Risk Assessment in Acute Myeloid Leukemia (Alliance)

Blood (2021) 138 (Supplement 1): 803.

https://doi.org/10.1182/blood-2021-147652

Published: 2021

Journal Articles

Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia (Alliance)

Sydney Fobare, Jessica Kohlschmidt, PhD, Hatice Gulcin Ozer, PhD, Krzysztof Mrózek, MDPhD, Deedra Nicolet, MS, Alice S. Mims, MD, Ramiro Garzon, MD, James S. Blachly, MD, Shelley Orwick, BS, Andrew J Carroll, PhD, Richard M. Stone, MD, Eunice S. Wang, MD, Jonathan E. Kolitz, MD, Bayard L. Powell, MD, Christopher C. Oakes, PhD, Ann-Kathrin Eisfeld, MD, Erin Hertlein, PhD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-135887

Published: 2020

Journal Articles

Differential Impact of Prognostically Significant Gene Mutations in Acute Myeloid Leukemia (AML) Patients (Pts) Older Than 70 Years (y) Treated with Cytarabine-Based Induction Therapy

Marius Bill, MD PhD, Jessica Kohlschmidt, PhD, Krzysztof Mrózek, MDPhD, Deedra Nicolet, MS, Christopher J. Walker, PhD, Dimitrios Papaioannou, MD, James S. Blachly, MD, Shelley Orwick, BS, Eunice S. Wang, MD, Jonathan E. Kolitz, MD, Bayard L. Powell, MD, Andrew J Carroll, PhD, Ramiro Garzon, MD, Richard M. Stone, MD, John C. Byrd, MD, Clara D. Bloomfield, MD, Ann-Kathrin Eisfeld, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-141663

Published: 2020

Journal Articles

Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-140999

Published: 2020

Journal Articles

Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BT K/PLCG2 mutations

Fabienne Lucas, Karylin Larkin, C. Thomas Gregory, Shelley Orwick, Tzyy-Jye Doong, Arletta Lozanski, Gerard Lozanski, Shrilekha Misra, Apollinaire Ngankeu, Hatice Gulcin Ozer, Deepa Sampath, Shanmugapriya Thangavadivel, Selen A. Yilmaz, Kerry A. Rogers, John C. Byrd, Jennifer A. Woyach, James S. Blachly

Blood (2020) 135 (24): 2192–2195.

https://doi.org/10.1182/blood.2019003722

Published: 2020

Includes: Supplemental data

Journal Articles

Rapid Molecular Diagnostics for Acute Myeloid Leukemia Using Single-Molecule Sequencing

Esko A. Kautto, BS, Charles Thomas Gregory, BS, Caner Saygin, MD, Shelley Orwick, BS, James S. Blachly, MD

Blood (2019) 134 (Supplement_1): 374.

https://doi.org/10.1182/blood-2019-131366

Published: 2019

Journal Articles

Genomic Analysis of Cellular Hierarchy in Acute Myeloid Leukemia Using Ultrasensitive LC-FACS-Seq

Caner Saygin, MD, Arletta Lozanski, Tzyy-Jye Doong, Shelley Orwick, BS, Deedra Nicolet, MS, Jadwiga Labanowska, Nyla A. Heerema, PhD, Rosa Lapalombella, PhD, Gregory K. Behbehani, MD PhD, John C. Byrd, MD, Gerard Lozanski, MD, James S. Blachly, MD

Blood (2019) 134 (Supplement_1): 186.

https://doi.org/10.1182/blood-2019-125285

Published: 2019

Journal Articles

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

Bhavana Bhatnagar, DO, Shelley Orwick, BS, Nyla A. Heerema, PhD, Alison R. Walker, MD, Alice S. Mims, MD, James S. Blachly, MD, Karilyn Larkin, MD, Nicole Grieselhuber, MD PhD, Gregory K. Behbehani, MD PhD, Apollinaire Ngankeu, Charles Thomas Gregory, BS, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1329.

https://doi.org/10.1182/blood-2019-130856

Published: 2019

NARROW

The Multi-CDK Inhibitor Dinaciclib Shows Synergistic Activity with the BET Inhibitor PLX51107 and Reverses BET Resistance through Inhibition of Canonical Wnt Signaling in Acute Myeloid Leukemia (AML)

Elucidating the Mechanism of Action (MOA) of Navtemadlin, an MDM2 Inhibitor, and Its Synergy with Gilteritinib in Myeloid Malignancies

Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])

Molecular and Clinical Features of FLT3 Juxtamembrane Domain Point Mutations (muts) in Acute Myeloid Leukemia (AML)

Identification of PTPN11 mutations As Early Events in the Development of Acute Myeloid Leukemia

Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study

High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance)

Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes

VIP152 Is a Novel CDK9 Inhibitor with Efficacy in Chronic Lymphocytic Leukemia

High-Dimensional Analysis Identifies Mechanisms of Gilteritinib Resistance in FLT3 -Mutated AML

Social Deprivation Independently Predicts Survival in Younger Patients with Acute Myeloid Leukemia (Alliance)

White Blood Cell Count (WBC) Levels Are Associated with Molecular Profiles and Are Independent Outcome Predictors in Acute Myeloid Leukemia (AML) Patients (Pts) (Alliance)

Epigenetic Phenocopying Expands Molecular Risk Assessment in Acute Myeloid Leukemia (Alliance)

Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia (Alliance)

Differential Impact of Prognostically Significant Gene Mutations in Acute Myeloid Leukemia (AML) Patients (Pts) Older Than 70 Years (y) Treated with Cytarabine-Based Induction Therapy

Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)

Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BT K/PLCG2 mutations

Rapid Molecular Diagnostics for Acute Myeloid Leukemia Using Single-Molecule Sequencing

Genomic Analysis of Cellular Hierarchy in Acute Myeloid Leukemia Using Ultrasensitive LC-FACS-Seq

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only